In Reply: Fibrinolysis has a proven role in
the treatment of myocardial infarction (MI) with ST-segment elevation. Glycoprotein
IIb/IIIa inhibition is established as an adjunct to primary percutaneous intervention
(PCI) for acute MI. The Global Use of Strategies To Open Occluded Coronary
Arteries (GUSTO) III trial examined the use of abciximab in patients who had
ongoing ischemia following fibrinolysis with full-dose reteplase or alteplase
and subsequently underwent rescue PCI with abciximab.1
There was a trend towards a lower 30-day mortality in the 83 patients who
received abciximab, although these patients did have more episodes of severe
bleeding. An analysis of the patients in Strategies for Patency Enhancement
in the Emergency Department (SPEED) who underwent PCI within 60 to 90 minutes
of receiving abciximab and reduced-dose reteplase revealed a low rate of mortality,
MI, or urgent revascularization at 30 days.2
Similarly, an analysis from the Integrilin and Reduced Dose of Thrombolytics
in Acute Myocardial Infarction (INTRO-AMI) trial showed that early PCI after
reduced-dose alteplase and eptifibatide also resulted in a relatively low
rate of death or reinfarction.3 This concept
of prompt chemical reperfusion followed by early PCI is now commonly referred
to as "facilitated PCI."
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 3
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
and access these and other features:
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.